Literature DB >> 16880196

Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

B M Lodde1, B J Baum, P P Tak, G Illei.   

Abstract

Sjögren's syndrome is an autoimmune exocrinopathy, mainly affecting the lacrimal and salivary glands, and resulting in ocular and oral dryness (keratoconjunctivitis sicca and xerostomia). The aetiology and pathogenesis are largely unknown, and only palliative treatment is currently available. Data obtained from experimental animal and human studies using biological agents or gene therapeutics can offer insight into the disease process of Sjögren's syndrome. This article reviews the current literature on these approaches and assesses the lessons learnt about the pathogenesis of Sjögren's syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880196      PMCID: PMC1798364          DOI: 10.1136/ard.2006.052761

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  82 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  LMO2 and gene therapy for severe combined immunodeficiency.

Authors:  Alain Fischer; Salima Hacein-Bey Abina; Adrian Thrasher; Christof von Kalle; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

Review 3.  Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA.

Authors:  Stanley R Pillemer; Janine Smith; Philip C Fox; Simon J Bowman
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

4.  Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome.

Authors:  J M van Woerkom; A A Kruize; M J G Wenting-van Wijk; E Knol; I C Bihari; J W G Jacobs; J W J Bijlsma; F P J G Lafeber; J A G van Roon
Journal:  Ann Rheum Dis       Date:  2005-04-07       Impact factor: 19.103

5.  Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.

Authors:  B M Lodde; F Mineshiba; J Wang; A P Cotrim; S Afione; P P Tak; B J Baum
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

Review 6.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

Review 7.  Antibodies against alpha-fodrin in Sjögren's syndrome.

Authors:  Kai U Ulbricht; Reinhold E Schmidt; Torsten Witte
Journal:  Autoimmun Rev       Date:  2003-03       Impact factor: 9.754

8.  Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.

Authors:  Vidya Sankar; Michael T Brennan; Marc R Kok; Rose Anne Leakan; Janine A Smith; Joan Manny; Bruce J Baum; Stanley R Pillemer
Journal:  Arthritis Rheum       Date:  2004-07

9.  Thalidomide. A promising new treatment for rheumatoid arthritis.

Authors:  O Gutiérrez-Rodríguez
Journal:  Arthritis Rheum       Date:  1984-10

10.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Nicolas Cagnard; Carlo Lucchesi; Franck Letourneur; Sylvie Mistou; Thierry Lazure; Sebastien Jacques; Nathalie Ba; Marc Ittah; Christine Lepajolec; Marc Labetoulle; Marc Ardizzone; Jean Sibilia; Catherine Fournier; Gilles Chiocchia; Xavier Mariette
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more
  1 in total

1.  Transcriptional modulation by VIP: a rational target against inflammatory disease.

Authors:  Hiba Ibrahim; Paul Barrow; Neil Foster
Journal:  Clin Epigenetics       Date:  2011-05-18       Impact factor: 6.551

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.